June 14, 2018 — The U.S. Food and Drug Administration (FDA) released the following two draft guidance documents:
- Coronary, Peripheral, and Neurovascular Guidewires - Performance Tests and Recommended Labeling; and
- Intravascular Catheters, Wires, and Delivery Systems with Lubricious Coatings - Labeling Considerations.
These guidance documents provide industry and FDA staff with recommendations on the least burdensome means of assessing the performance of catheters, guidewires and delivery systems submitted in premarket approval applications (PMAs) or premarket notification (510(k)s).
The “Coronary, Peripheral, and Neurovascular Guidewires - Performance Tests and Recommended Labeling” draft guidance provides draft recommendations for 510(k) submissions for certain guidewires intended for use in the coronary, peripheral and neurovasculature. This draft guidance includes recommendations for descriptive characteristics, labeling, biocompatibility, sterility, non-clinical testing and animal/clinical performance testing. When finalized, this guidance will supersede the 1995 Coronary and Cerebrovascular Guidewire Guidance.
The “Intravascular Catheters, Wires, and Delivery Systems with Lubricious Coatings - Labeling Considerations” draft guidance addresses labeling considerations for devices containing lubricious coatings used in the vasculature, some of which are also within the scope of the above-referenced guidewire guidance. The guidance recommendations are based on information received and analyzed by FDA concerning serious adverse events associated with hydrophilic and/or hydrophobic coatings separating (e.g., peeling, flaking, shedding, delaminating, sloughing off) from intravascular medical devices; for more details see FDA Safety Communication for Lubricious Coating Separation from Intravascular Medical Devices issued on Nov. 23, 2015. This guidance document is intended to enhance the consistency of coating-related information in marketing submissions as well as promote the safe use of these devices in the clinical setting.
The FDA welcomes comments regarding these draft guidance documents. The comment period will be open for 60 days in the Federal Register under docket numbers FDA-2018-D-1775 and FDA-2018-D-1788, starting June 15, 2018.
For more information: www.fda.gov
Related Guidewire Content
The Basics of Guide Wire Technology
Understanding the Design and Function of Guidewire Technology
VIDEO: Basics of Interventional Guidewire Design and Function, an interview with guidewire expert Dimitri Karmpaliotis, M.D., Ph.D., FACC, professor of medicine, Columbia University Medical Center, and director of CTO, complex and high-risk angioplasty program at the Center for Interventional Vascular Therapy, NewYork-Presbyterian Hospital.
December 20, 2023 
